|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Novel Fusion Protein Pharmaceuticals for Autoimmune Diseases |
|
| Management |
| Dr. Noam Shani, CEO |
| |
|
|
| |
|
| Keywords |
| Immunology. Autoimmune Disease, Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Lupus |
|
|
|
| Description |
|
KAHR focuses on the development of novel fusion protein pharmaceuticals for the treatment of autoimmune diseases. Autoimmune diseases affect over five percent of the world population and encompass devastating conditions such as rheumatoid arthritis, multiple sclerosis, psoriasis, and systemic lupus erythematosus. |
|
| Products / Services |
KAHR Medical has selected two of the investigated TSCP candidates, TSCP-1 and TSCP-2, for its drug development pipeline. Both drug candidates are currently in GMP cell-line development towards clinical studies
|
|
| Technology / Differentiation |
| Conventional protein therapeutics are comprised of a single functional unit that mediates one primary function -- such as blocking a specific receptor or ligand. In contrast, KAHR Medical's technology integrates two functional units, enabling them to elicit multiple self-reinforcing functional endpoints. Typically, each TSCP will connect a portion of a type I membrane protein (at the fusion protein's N-terminus) with a portion of a type II membrane protein (at the fusion protein's C-terminus). The result is superior activity and specificity, with therapeutic benefits that cannot be achieved simply by administering the TSCP component elements as separate units. |
|
| Market / Customers |
Overall, KAHR's target market of therapeutics for autoimmune diseases is estimated at over $ 30 billion per year. The autoimmune drug market has grown over the last decades and is expected to continue to grow, due to as yet unmet clinical needs. The autoimmune market has been the major target for many of the leading protein-based blockbuster drugs, such as Remicade, Enbrel, Rituxan and Humira, with sales exceeding $ 20 billion in 2006.
|
|
| Status |
| The company is seeking additional investment to support initiation of clinical studies in 2009. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members